Morphinan-3-ol, 17-(2-propenyl)-

• 分子结构分类: 有机化合物 - 生物碱及其衍生物 - 吗啡烷
• 英文名称: Morphinan-3-ol, 17-(2-propenyl)-
• 英文别名: 17-prop-2-enyl-17-azatetracyclo[7.5.3.01,10.02,7]heptadeca-2(7),3,5-trien-4-ol
• 化学式: C₁₉H₂₅NO
• 分子量: 283.4
• InChiKey: OZYUPQUCAUTOBP-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.5
• 重原子数：
  21
• 可旋转键数：
  2
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.58
• 拓扑面积：
  23.5
• 氢给体数：
  1
• 氢受体数：
  2

文献信息

• Pharmaceutical preparation containing copolyvidone
  申请人：Takeda Pharmaceutical Company Limited

  公开号：US10098866B2

  公开（公告）日：2018-10-16

  A stabilized preparation which comprises: a unstable drug in a polyethylene glycol-containing preparation; and a coating agent comprising a copolyvidone instead of polyethylene glycol with which the drug is coated.

  一种稳定的制剂，包括：在聚乙二醇含制剂中的不稳定药物；以及一种包衣剂，其包衣剂包括一种共聚维酮，而不是用聚乙二醇包衣药物。
• Sulfur(VI) fluoride compounds and methods for the preparation thereof
  申请人：The Scripps Research Institute

  公开号：US10117840B2

  公开（公告）日：2018-11-06

  This application describes a compound represented by Formula (I): (I) wherein: Y is a biologically active organic core group comprising one or more of an aryl group, a heteroaryl aryl group, a nonaromatic hydrocarbyl group, and a nonaromatic heterocyclic group, to which Z is covalently bonded; n is 1, 2, 3, 4 or 5; m is 1 or 2; Z is O, NR, or N; X1 is a covalent bond or —CH2CH2—, X2 is O or NR; and R comprises H or a substituted or unsubstituted group selected from an aryl group, a heteroaryl aryl group, a nonaromatic hydrocarbyl group, and a nonaromatic heterocyclic group. Methods of preparing the compounds, methods of using the compounds, and pharmaceutical compositions comprising the compounds are described as well.

  该应用描述了由式(I)表示的化合物：(I)其中：Y是一个生物活性有机核心基团，包括芳基、杂芳基、非芳香烃基和非芳香杂环基中的一个或多个，其中Z与之以共价键结合；n为1、2、3、4或5；m为1或2；Z为O、NR或N；X1为共价键或—CH2CH2—，X2为O或NR；R包括H或从芳基、杂芳基、非芳香烃基和非芳香杂环基中选择的取代或未取代基团。还描述了制备这些化合物的方法、使用这些化合物的方法以及包含这些化合物的药物组合物。
• Benzimidazolone and quinazolinone derivatives as agonists on human ORL1 receptors
  申请人：Den Hartog A.J. Jacobus

  公开号：US20050070528A1

  公开（公告）日：2005-03-31

  The invention relates to a group of novel benzimidazolone and quinazolinone derivatives which are agonists on human ORL1 (nociceptin) receptors. The invention also relates to the preparation of these compounds, to pharmaceutical compositions containing a pharmacologically active amount of at least one of these imidazolone and quinazolinone derivatives as an active ingredient, as well as to the use of these pharmaceutical compositions for the treatment of disorders in which ORL1 receptors are involved. The invention relates to compounds of the general formula (1): wherein the symbols have the meanings as given in the description.

  该发明涉及一组新型苯并咪唑酮和喹唑酮衍生物，这些衍生物是人类ORL1（nociceptin）受体的激动剂。该发明还涉及制备这些化合物，含有至少一种这些咪唑酮和喹唑酮衍生物的药理活性量作为活性成分的药物组合物，以及利用这些药物组合物治疗涉及ORL1受体的疾病。该发明涉及一般公式（1）的化合物：其中符号的含义如描述中所述。
• Hydrogel-containing medical articles and methods of using and making the same
  申请人：Faure Marie-Pierre

  公开号：US20050214376A1

  公开（公告）日：2005-09-29

  Medical articles including a hydrophilic water-swellable hydrogel and methods of using and making the articles are provided. The hydrogel may include a crosslinked mixture of a biocompatible polymer and a protein, such as polyethylene glycol and a soy protein. The hydrogel may further include an agent, such as diazolidinyl urea and iodopropynyl butylcarbamate, dispersed within the hydrophilic water-swellable hydrogel.

  提供了包括亲水性水膨胀性水凝胶的医疗文章以及使用和制作这些文章的方法。水凝胶可能包括生物相容性聚合物和蛋白质的交联混合物，例如聚乙二醇和大豆蛋白。水凝胶还可能在亲水性水膨胀性水凝胶中分散了一种药剂，如二嗪基脲和碘丙炔丁基氨基甲酸酯。
• External preparation for skin diseases containing nitroimidazole
  申请人：——

  公开号：US20030092754A1

  公开（公告）日：2003-05-15

  An external preparation for skin disease which comprises a nitroimidazole derivative represented by the following formula (I): 1 wherein R 1 , R 3 and R 4 may be the same or different and represent a hydrogen atom, a nitro group, a lower alkyl group, a substituted lower alkyl group, a lower alkenyl group, or a substituted lower alkenyl group; and R 2 represents a hydrogen atom, a lower alkyl group, a substituted lower alkyl group and a lower alkenyl group or a substituted lower alkenyl group, provided that any one of R 1 , R 3 and R 4 is a nitro group.

  一种外用制剂，用于皮肤疾病，包括以下式(I)所代表的硝基咪唑衍生物：1其中R1、R3和R4可以相同也可以不同，并表示氢原子、硝基、低烷基、取代的低烷基、低烯基或取代的低烯基；R2表示氢原子、低烷基、取代的低烷基和低烯基或取代的低烯基，只要R1、R3和R4中的任何一个是硝基。

表征谱图